Table IV.
Distribution of presence and absence of prediabetes per score category and corresponding sensitivity, specificity, and predictive values when dichotomized at different cutoff points
| Development stage | ||||||
|---|---|---|---|---|---|---|
| Risk category | Prediabetes (n = 8.911) | Normal (n = 12.809) | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) |
| VLR (score 0–6), n = 6.374 | 1.767 | 4.607 | ||||
| LR (score 7), n = 6.685 | 2.686 | 3.999 | 80.17 (79.33–80.99) | 35.97 (35.14–36.80) | 46.55 (46.14–46.97) | 72.28 (71.31–73.22) |
| MR (score 12), n = 8.285 | 4.249 | 4.036 | 50.03 (48.98–51.07) | 67.19 (66.37–68.00) | 51.47 (50.66–52.28) | 65.90 (65.36–66.44) |
| HR (score 18), n = 376 | 209 | 167 | 2.35 (2.04–2.68) | 98.70 (98.48–98.89) | 55.59 (50.57–60.49) | 59.23 (59.14–59.32) |
| Validation stage | ||||||
| Risk category | Prediabetes (n = 548) | Normal (n = 6.385) | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) |
| VLR (score 0–6), n = 2.451 | 90 | 2.361 | ||||
| LR (score 7), n = 1.997 | 156 | 1.841 | 83.58 (80.20–86.58) | 36.98 (35.79–38.17) | 10.22 (9.84–10.61) | 96.33 (95.59–96.95) |
| MR (score 12), n = 2.366 | 286 | 2.080 | 55.11 (50.84–59.33) | 65.81 (64.63–66.97) | 12.15 (11.30–13.07) | 94.47 (93.95–94.94) |
| HR (score 18), n = 119 | 16 | 103 | 2.92 (1.68–4.70) | 98.39 (98.05–98.68) | 13.45 (8.46–20.71) | 92.19 (92.08–92.30) |
In development stage: AUC = 0.623 (95% CI 0.616–0.631), whereas in validation stage by random plasma glucose [n = 6.993; AUC = 0.646 (95% CI 0.623–0.669); Hosmer–Lemeshow test, p < 0.001]